{
    "xml": "<topic id=\"PHP6653\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/tocilizumab\" basename=\"tocilizumab\" title=\"TOCILIZUMAB\">\n<title>TOCILIZUMAB</title>\n<body>\n<data name=\"vtmid\">444649004</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_649595817\" title=\"Interleukin inhibitors\">Interleukin inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n</body>\n<topic id=\"PHP35393\" outputclass=\"indicationsAndDose\" rev=\"1.43\" parent=\"/drugs/tocilizumab\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Moderate to severe active rheumatoid arthritis (in combination with methotrexate or alone if methotrexate inappropriate) when response to at least one disease-modifying antirheumatic drug or tumour necrosis factor inhibitor has been inadequate, or in those who are intolerant of these drugs</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>8&#8239;mg/kg every 4&#8239;weeks (max. per dose 800&#8239;mg), for dose adjustments in patients with liver enzyme abnormalities, or low absolute neutrophil or platelet count, consult product literature.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35420\" outputclass=\"contraindications\" rev=\"1.10\" parent=\"/drugs/tocilizumab\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Do not initiate if absolute neutrophil count less than 2 x 10<sup>9</sup>/litre</ph>; <ph outputclass=\"contraindication\">severe active infection</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35434\" outputclass=\"cautions\" rev=\"1.27\" parent=\"/drugs/tocilizumab\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">History of diverticulitis</ph>; <ph outputclass=\"caution\">history of intestinal ulceration</ph>; <ph outputclass=\"caution\">history of recurrent or chronic infection (interrupt treatment if serious infection occurs)</ph>; <ph outputclass=\"caution\">low absolute neutrophil count</ph>; <ph outputclass=\"caution\">low platelet count</ph>; <ph outputclass=\"caution\">predisposition to infection (interrupt treatment if serious infection occurs)</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Tuberculosis</p>\n<p>Patients with latent tuberculosis should be treated with standard therapy before starting tocilizumab.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35389\" outputclass=\"interactions\" rev=\"1.9\" parent=\"/drugs/tocilizumab\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (tocilizumab).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35373\" outputclass=\"sideEffects\" rev=\"1.26\" parent=\"/drugs/tocilizumab\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<title>General side-effects:</title>\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">antibody formation</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">gastritis</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypercholesterolaemia</ph>; <ph outputclass=\"sideEffect\">hypersensitivity</ph>; <ph outputclass=\"sideEffect\">hypertension</ph>; <ph outputclass=\"sideEffect\">infection</ph>; <ph outputclass=\"sideEffect\">leucopenia</ph>; <ph outputclass=\"sideEffect\">mouth ulceration</ph>; <ph outputclass=\"sideEffect\">neutropenia</ph>; <ph outputclass=\"sideEffect\">peripheral oedema</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">raised hepatic transaminases</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">upper respiratory-tract infection</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anaphylaxis</ph>; <ph outputclass=\"sideEffect\">gastric ulcer</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal perforation</ph>; <ph outputclass=\"sideEffect\">hypertriglyceridaemia</ph>; <ph outputclass=\"sideEffect\">hypothyroidism</ph>; <ph outputclass=\"sideEffect\">nephrolithiasis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Thrombocytopenia</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"specificSideEffects\">\n<title>Specific side-effects:</title>\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<sectiondiv outputclass=\"sideEffectsWithRoutes\">\n<p outputclass=\"title\">With intravenous use</p>\n<p>\n<ph outputclass=\"sideEffect\">infusion related reactions</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Neutrophil and platelet counts</p>\n<p>Discontinue if absolute neutrophil count less than 0.5 x 10<sup>9</sup>/litre or platelet count less than 50 x 10<sup>3</sup>/microlitre).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35428\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/tocilizumab\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Effective contraception required during and for 3 months after treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35383\" outputclass=\"pregnancy\" parent=\"/drugs/tocilizumab\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid unless essential&#8212;toxicity in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35442\" outputclass=\"breastFeeding\" parent=\"/drugs/tocilizumab\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises use only if potential benefit outweighs risk&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35400\" outputclass=\"hepaticImpairment\" parent=\"/drugs/tocilizumab\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution&#8212;consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35377\" outputclass=\"renalImpairment\" parent=\"/drugs/tocilizumab\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises monitor renal function closely in moderate or severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35376\" outputclass=\"preTreatmentScreening\" rev=\"1.8\" parent=\"/drugs/tocilizumab\">\n<title>Pre-treatment screening</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Tuberculosis</p>\n<p>Patients should be evaluated for tuberculosis before treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35363\" outputclass=\"monitoringRequirements\" parent=\"/drugs/tocilizumab\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor hepatic transaminases every 4&#8211;8 weeks for first 6 months, then every 12 weeks.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Monitor neutrophil and platelet counts 4&#8211;8 weeks after starting treatment and then as indicated.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Monitor lipid profile 4&#8211;8 weeks after starting treatment and then as indicated.</p>\n<p>Monitor for demyelinating disorders.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35459\" outputclass=\"directionsForAdministration\" rev=\"1.20\" parent=\"/drugs/tocilizumab\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i> (<i>RoActemra</i>\n<tm tmtype=\"reg\"/>), give intermittently in Sodium chloride 0.9%; dilute requisite dose to a volume of 100&#8239;mL with infusion fluid and give over 1 hour. </p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35379\" outputclass=\"patientAndCarerAdvice\" rev=\"1.22\" parent=\"/drugs/tocilizumab\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"patientResources\">\n<sectiondiv>\n<p>An alert card should be provided.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patients and their carers should be advised to seek immediate medical attention if symptoms of infection occur, or if symptoms of diverticular perforation such as abdominal pain, haemorrhage, or fever accompanying change in bowel habits occur.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35356\" outputclass=\"nationalFunding\" rev=\"1.22\" parent=\"/drugs/tocilizumab\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA247</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Tocilizumab for the treatment of rheumatoid arthritis (February 2012)</p>\r\n<p>Tocilizumab, in combination with methotrexate, is recommended as an option for the treatment of rheumatoid arthritis in adults if:</p>\r\n<ul>\r\n<li>the disease has responded inadequately to disease-modifying anti-rheumatic drugs (DMARDs) <b>and</b> is used as described for tumour necrosis factor (TNF) inhibitor treatments (specifically the recommendations on disease activity and treatment) in the NICE guidance (October 2007) Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis, <i>or</i>\r\n</li>\r\n<li>the disease has responded inadequately to DMARDs and a TNF inhibitor and the patient cannot receive rituximab because of contra-indications or intolerance, <b>and</b> tocilizumab is used as described for TNF inhibitor treatments (specifically the recommendations on disease activity) in the NICE guidance (August 2010) Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor, <i>or</i>\r\n</li>\r\n<li>the disease has responded inadequately to one or more TNF inhibitor treatments and to rituximab</li>\r\n<li>\r\n<b>and</b> the manufacturer provides tocilizumab with the discount agreed as part of the patient access scheme.</li>\r\n</ul>\r\n<p>Patients currently receiving tocilizumab for the treatment of rheumatoid arthritis who do not meet these criteria should have the option to continue treatment until they and their clinicians consider it appropriate to stop.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA247\">www.nice.org.uk/TA247</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (August 2012) that tocilizumab (<i>RoActemra</i>\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland as monotherapy in patients who are intolerant to methotrexate or where continued treatment with methotrexate is inappropriate, for the treatment of moderate to severe active rheumatoid arthritis in adults who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying antirheumatic drugs or tumour necrosis factor inhibitors, in accordance with the British Society for Rheumatology guidance on prescribing TNF-&#945; blockers in adults with rheumatoid arthritis (2005).</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP6653-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/tocilizumab\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP101344\" title=\"Solution for injection\" namespace=\"/drugs/tocilizumab/solution-for-injection\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76723\" title=\"Solution for infusion\" namespace=\"/drugs/tocilizumab/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78421\" namespace=\"/treatment-summaries/rheumatic-disease-suppressing-drugs\" title=\"Rheumatic disease, suppressing drugs\" count=\"3\" rel=\"backlink\">Rheumatic disease, suppressing drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP101344\" namespace=\"/drugs/tocilizumab/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76723\" namespace=\"/drugs/tocilizumab/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP6653",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/tocilizumab",
    "basename": "tocilizumab",
    "title": "TOCILIZUMAB",
    "vtmid": "444649004",
    "drugClassification": [
        "Interleukin inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Moderate to severe active rheumatoid arthritis (in combination with methotrexate or alone if methotrexate inappropriate) when response to at least one disease-modifying antirheumatic drug or tumour necrosis factor inhibitor has been inadequate, or in those who are intolerant of these drugs",
                        "html": "Moderate to severe active rheumatoid arthritis (in combination with methotrexate or alone if methotrexate inappropriate) when response to at least one disease-modifying antirheumatic drug or tumour necrosis factor inhibitor has been inadequate, or in those who are intolerant of these drugs"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "8 mg/kg every 4 weeks (max. per dose 800 mg), for dose adjustments in patients with liver enzyme abnormalities, or low absolute neutrophil or platelet count, consult product literature.",
                        "html": "<p>8&#8239;mg/kg every 4&#8239;weeks (max. per dose 800&#8239;mg), for dose adjustments in patients with liver enzyme abnormalities, or low absolute neutrophil or platelet count, consult product literature.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Do not initiate if absolute neutrophil count less than 2 x 109/litre",
                "html": "Do not initiate if absolute neutrophil count less than 2 x 10<sup>9</sup>/litre"
            },
            {
                "type": "contraindications",
                "textContent": "severe active infection",
                "html": "severe active infection"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "History of diverticulitis",
                "html": "History of diverticulitis"
            },
            {
                "type": "cautions",
                "textContent": "history of intestinal ulceration",
                "html": "history of intestinal ulceration"
            },
            {
                "type": "cautions",
                "textContent": "history of recurrent or chronic infection (interrupt treatment if serious infection occurs)",
                "html": "history of recurrent or chronic infection (interrupt treatment if serious infection occurs)"
            },
            {
                "type": "cautions",
                "textContent": "low absolute neutrophil count",
                "html": "low absolute neutrophil count"
            },
            {
                "type": "cautions",
                "textContent": "low platelet count",
                "html": "low platelet count"
            },
            {
                "type": "cautions",
                "textContent": "predisposition to infection (interrupt treatment if serious infection occurs)",
                "html": "predisposition to infection (interrupt treatment if serious infection occurs)"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Tuberculosis",
                "textContent": "Patients with latent tuberculosis should be treated with standard therapy before starting tocilizumab.",
                "html": "<p>Patients with latent tuberculosis should be treated with standard therapy before starting tocilizumab.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (tocilizumab).",
                "html": "<p>Appendix 1 (tocilizumab).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "antibody formation",
                        "html": "antibody formation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "gastritis",
                        "html": "gastritis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypercholesterolaemia",
                        "html": "hypercholesterolaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypersensitivity",
                        "html": "hypersensitivity",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypertension",
                        "html": "hypertension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "infection",
                        "html": "infection",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "leucopenia",
                        "html": "leucopenia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "mouth ulceration",
                        "html": "mouth ulceration",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "neutropenia",
                        "html": "neutropenia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "peripheral oedema",
                        "html": "peripheral oedema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "raised hepatic transaminases",
                        "html": "raised hepatic transaminases",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "upper respiratory-tract infection",
                        "html": "upper respiratory-tract infection",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Anaphylaxis",
                        "html": "Anaphylaxis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "gastric ulcer",
                        "html": "gastric ulcer",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "gastro-intestinal perforation",
                        "html": "gastro-intestinal perforation",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hypertriglyceridaemia",
                        "html": "hypertriglyceridaemia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hypothyroidism",
                        "html": "hypothyroidism",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "nephrolithiasis",
                        "html": "nephrolithiasis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Thrombocytopenia",
                        "html": "Thrombocytopenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "specific": {
            "frequencies": {
                "uncommon": [
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "infusion related reactions",
                        "html": "infusion related reactions",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Neutrophil and platelet counts",
                "textContent": "Discontinue if absolute neutrophil count less than 0.5 x 109/litre or platelet count less than 50 x 103/microlitre).",
                "html": "<p>Discontinue if absolute neutrophil count less than 0.5 x 10<sup>9</sup>/litre or platelet count less than 50 x 10<sup>3</sup>/microlitre).</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Effective contraception required during and for 3 months after treatment.",
                "html": "<p>Effective contraception required during and for 3 months after treatment.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid unless essential&#8212;toxicity in animal studies.",
                "html": "<p>Manufacturer advises avoid unless essential&#8212;toxicity in <i>animal</i> studies.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises use only if potential benefit outweighs risk&#8212;no information available.",
                "html": "<p>Manufacturer advises use only if potential benefit outweighs risk&#8212;no information available.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution&#8212;consult product literature.",
                "html": "<p>Manufacturer advises caution&#8212;consult product literature.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises monitor renal function closely in moderate or severe impairment.",
                "html": "<p>Manufacturer advises monitor renal function closely in moderate or severe impairment.</p>"
            }
        ]
    },
    "preTreatmentScreening": {
        "preTreatmentScreening": [
            {
                "type": "preTreatmentScreening",
                "title": "Tuberculosis",
                "textContent": "Patients should be evaluated for tuberculosis before treatment.",
                "html": "<p>Patients should be evaluated for tuberculosis before treatment.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor hepatic transaminases every 4&#8211;8 weeks for first 6 months, then every 12 weeks.",
                "html": "<p>Monitor hepatic transaminases every 4&#8211;8 weeks for first 6 months, then every 12 weeks.</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "Monitor neutrophil and platelet counts 4&#8211;8 weeks after starting treatment and then as indicated.",
                "html": "<p>Monitor neutrophil and platelet counts 4&#8211;8 weeks after starting treatment and then as indicated.</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "Monitor lipid profile 4&#8211;8 weeks after starting treatment and then as indicated.\n\nMonitor for demyelinating disorders.",
                "html": "<p>Monitor lipid profile 4&#8211;8 weeks after starting treatment and then as indicated.</p><p>Monitor for demyelinating disorders.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (RoActemra ), give intermittently in Sodium chloride 0.9%; dilute requisite dose to a volume of 100 mL with infusion fluid and give over 1 hour.",
                "html": "<p>For <i>intravenous infusion</i> (<i>RoActemra</i>\n<tm tmtype=\"reg\"/>), give intermittently in Sodium chloride 0.9%; dilute requisite dose to a volume of 100&#8239;mL with infusion fluid and give over 1 hour. </p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientResources": [
            {
                "type": "patientResources",
                "textContent": "An alert card should be provided.",
                "html": "<p>An alert card should be provided.</p>"
            }
        ],
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients and their carers should be advised to seek immediate medical attention if symptoms of infection occur, or if symptoms of diverticular perforation such as abdominal pain, haemorrhage, or fever accompanying change in bowel habits occur.",
                "html": "<p>Patients and their carers should be advised to seek immediate medical attention if symptoms of infection occur, or if symptoms of diverticular perforation such as abdominal pain, haemorrhage, or fever accompanying change in bowel habits occur.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA247",
                        "label": "www.nice.org.uk/TA247"
                    }
                ],
                "fundingIdentifier": "NICE TA247",
                "textContent": "Tocilizumab for the treatment of rheumatoid arthritis (February 2012) Tocilizumab, in combination with methotrexate, is recommended as an option for the treatment of rheumatoid arthritis in adults if: the disease has responded inadequately to disease-modifying anti-rheumatic drugs (DMARDs) and is used as described for tumour necrosis factor (TNF) inhibitor treatments (specifically the recommendations on disease activity and treatment) in the NICE guidance (October 2007) Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis, or the disease has responded inadequately to DMARDs and a TNF inhibitor and the patient cannot receive rituximab because of contra-indications or intolerance, and tocilizumab is used as described for TNF inhibitor treatments (specifically the recommendations on disease activity) in the NICE guidance (August 2010) Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor, or the disease has responded inadequately to one or more TNF inhibitor treatments and to rituximab and the manufacturer provides tocilizumab with the discount agreed as part of the patient access scheme. Patients currently receiving tocilizumab for the treatment of rheumatoid arthritis who do not meet these criteria should have the option to continue treatment until they and their clinicians consider it appropriate to stop.\n\nwww.nice.org.uk/TA247",
                "html": "<p outputclass=\"title\">Tocilizumab for the treatment of rheumatoid arthritis (February 2012)</p> <p>Tocilizumab, in combination with methotrexate, is recommended as an option for the treatment of rheumatoid arthritis in adults if:</p> <ul> <li>the disease has responded inadequately to disease-modifying anti-rheumatic drugs (DMARDs) <b>and</b> is used as described for tumour necrosis factor (TNF) inhibitor treatments (specifically the recommendations on disease activity and treatment) in the NICE guidance (October 2007) Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis, <i>or</i> </li> <li>the disease has responded inadequately to DMARDs and a TNF inhibitor and the patient cannot receive rituximab because of contra-indications or intolerance, <b>and</b> tocilizumab is used as described for TNF inhibitor treatments (specifically the recommendations on disease activity) in the NICE guidance (August 2010) Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor, <i>or</i> </li> <li>the disease has responded inadequately to one or more TNF inhibitor treatments and to rituximab</li> <li> <b>and</b> the manufacturer provides tocilizumab with the discount agreed as part of the patient access scheme.</li> </ul> <p>Patients currently receiving tocilizumab for the treatment of rheumatoid arthritis who do not meet these criteria should have the option to continue treatment until they and their clinicians consider it appropriate to stop.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA247\">www.nice.org.uk/TA247</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP101344",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76723",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78421",
                "label": "Rheumatic disease, suppressing drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP101344",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76723",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}